FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145595818> ?p ?o ?g. }

• W2145595818 endingPage "1303" @default.
• W2145595818 startingPage "1300" @default.
• W2145595818 abstract "The tolerability of azacitidine (AZA) allows its administration in elderly patients. The objective of this study was to analyze the clinical and biological characteristics, transfusion independence (TI), overall survival (OS) and toxicity in a series of 107 patients ≥ 75 years of age from the Spanish Registry of Myelodysplastic Syndromes (MDS) treated with AZA. The median age (range) was 78 (75–90) years. According to the World Health Organization (WHO) classification, 86/102 (84%) had MDS, 10/102 (10%) had mixed myeloproferative/myelodysplastic disorder and 6/102 (6%) had acute myeloblastic leukemia. Regarding MDS by the International Prognostic Scoring System on initiation of AZA, 38/84 (45%) were low–intermediate-1 risk and 46/84 (55%) were intermediate-2–high risk. Ninety-five patients (89%) were red blood cell or platelet transfusion dependent. The AZA schedule was 5-0-0 in 39/106 (37%) patients, 5-2-2 in 36/106 (34%) patients and 7 consecutive days in 31/106 (29%) patients. The median number of cycles administered was 8 (range, 1–30). Thirty-eight out of 94 (40%) patients achieved TI. Median OS (95% confidence interval [CI]) was significantly better in patients achieving TI (n = 38) compared to patients who did not (n = 56) (22 [20.1–23.9] months vs. 11.1 [4.8–17.5] months, p = 0.001). No significant differences were observed in TI rate and OS among the three different schedules. With a median follow-up of 14 (min–max, 1–50) months, the median OS (95% CI) of the 107 patients was 18 (12–23) months and the probability of OS (95% CI) at 2 years was 34% (22–46%). Cycles were delayed in 31/106 (29%) patients and 47/101 patients (47%) were hospitalized for infection. These results show that treatment with AZA was feasible and effective in this elderly population, with 40% achieving TI, having a better OS than patients not achieving it. The schedule of AZA administration did not affect efficacy and toxicity." @default.
• W2145595818 created "2016-06-24" @default.
• W2145595818 creator A5003711904 @default.
• W2145595818 creator A5004347563 @default.
• W2145595818 creator A5006173909 @default.
• W2145595818 creator A5017441186 @default.
• W2145595818 creator A5025056334 @default.
• W2145595818 creator A5025336034 @default.
• W2145595818 creator A5025528565 @default.
• W2145595818 creator A5026592803 @default.
• W2145595818 creator A5030407146 @default.
• W2145595818 creator A5035866456 @default.
• W2145595818 creator A5044373324 @default.
• W2145595818 creator A5045863854 @default.
• W2145595818 creator A5046427451 @default.
• W2145595818 creator A5053367608 @default.
• W2145595818 creator A5056210253 @default.
• W2145595818 creator A5056386020 @default.
• W2145595818 creator A5062178541 @default.
• W2145595818 creator A5062844986 @default.
• W2145595818 creator A5064707480 @default.
• W2145595818 creator A5067159029 @default.
• W2145595818 creator A5069231480 @default.
• W2145595818 creator A5070214645 @default.
• W2145595818 creator A5074130459 @default.
• W2145595818 creator A5077115057 @default.
• W2145595818 creator A5078589511 @default.
• W2145595818 creator A5080697191 @default.
• W2145595818 creator A5084354003 @default.
• W2145595818 creator A5085044593 @default.
• W2145595818 creator A5085610729 @default.
• W2145595818 creator A5088290488 @default.
• W2145595818 creator A5088848336 @default.
• W2145595818 creator A5089140665 @default.
• W2145595818 date "2013-09-16" @default.
• W2145595818 modified "2023-10-17" @default.
• W2145595818 title "Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes" @default.
• W2145595818 cites W187238933 @default.
• W2145595818 cites W1988267450 @default.
• W2145595818 cites W1988907854 @default.
• W2145595818 cites W2035936232 @default.
• W2145595818 cites W2080584244 @default.
• W2145595818 cites W2106584820 @default.
• W2145595818 cites W2118771330 @default.
• W2145595818 cites W2129510594 @default.
• W2145595818 cites W2145728897 @default.
• W2145595818 cites W2148968593 @default.
• W2145595818 cites W2157287007 @default.
• W2145595818 cites W4253916874 @default.
• W2145595818 cites W4293241248 @default.
• W2145595818 cites W4298434897 @default.
• W2145595818 doi "https://doi.org/10.3109/10428194.2013.834532" @default.
• W2145595818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23952246" @default.
• W2145595818 hasPublicationYear "2013" @default.
• W2145595818 type Work @default.
• W2145595818 sameAs 2145595818 @default.
• W2145595818 citedByCount "15" @default.
• W2145595818 countsByYear W21455958182012 @default.
• W2145595818 countsByYear W21455958182014 @default.
• W2145595818 countsByYear W21455958182015 @default.
• W2145595818 countsByYear W21455958182016 @default.
• W2145595818 countsByYear W21455958182017 @default.
• W2145595818 countsByYear W21455958182018 @default.
• W2145595818 countsByYear W21455958182019 @default.
• W2145595818 countsByYear W21455958182020 @default.
• W2145595818 countsByYear W21455958182021 @default.
• W2145595818 countsByYear W21455958182022 @default.
• W2145595818 crossrefType "journal-article" @default.
• W2145595818 hasAuthorship W2145595818A5003711904 @default.
• W2145595818 hasAuthorship W2145595818A5004347563 @default.
• W2145595818 hasAuthorship W2145595818A5006173909 @default.
• W2145595818 hasAuthorship W2145595818A5017441186 @default.
• W2145595818 hasAuthorship W2145595818A5025056334 @default.
• W2145595818 hasAuthorship W2145595818A5025336034 @default.
• W2145595818 hasAuthorship W2145595818A5025528565 @default.
• W2145595818 hasAuthorship W2145595818A5026592803 @default.
• W2145595818 hasAuthorship W2145595818A5030407146 @default.
• W2145595818 hasAuthorship W2145595818A5035866456 @default.
• W2145595818 hasAuthorship W2145595818A5044373324 @default.
• W2145595818 hasAuthorship W2145595818A5045863854 @default.
• W2145595818 hasAuthorship W2145595818A5046427451 @default.
• W2145595818 hasAuthorship W2145595818A5053367608 @default.
• W2145595818 hasAuthorship W2145595818A5056210253 @default.
• W2145595818 hasAuthorship W2145595818A5056386020 @default.
• W2145595818 hasAuthorship W2145595818A5062178541 @default.
• W2145595818 hasAuthorship W2145595818A5062844986 @default.
• W2145595818 hasAuthorship W2145595818A5064707480 @default.
• W2145595818 hasAuthorship W2145595818A5067159029 @default.
• W2145595818 hasAuthorship W2145595818A5069231480 @default.
• W2145595818 hasAuthorship W2145595818A5070214645 @default.
• W2145595818 hasAuthorship W2145595818A5074130459 @default.
• W2145595818 hasAuthorship W2145595818A5077115057 @default.
• W2145595818 hasAuthorship W2145595818A5078589511 @default.
• W2145595818 hasAuthorship W2145595818A5080697191 @default.
• W2145595818 hasAuthorship W2145595818A5084354003 @default.
• W2145595818 hasAuthorship W2145595818A5085044593 @default.
• W2145595818 hasAuthorship W2145595818A5085610729 @default.
• W2145595818 hasAuthorship W2145595818A5088290488 @default.

• next